PE20120080A1 - Anticuerpos anti-notch2 y metodos de uso - Google Patents
Anticuerpos anti-notch2 y metodos de usoInfo
- Publication number
- PE20120080A1 PE20120080A1 PE2011000807A PE2011000807A PE20120080A1 PE 20120080 A1 PE20120080 A1 PE 20120080A1 PE 2011000807 A PE2011000807 A PE 2011000807A PE 2011000807 A PE2011000807 A PE 2011000807A PE 20120080 A1 PE20120080 A1 PE 20120080A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- nos
- methods
- selected sequences
- notch2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
REFERIDA A UN ANTICUERPO MONOCLONAL QUE SEFIJA A Notch2 NRR CARACTERIZADA POR: A) UN HVR-H1 DE SECUENCIAS SELECCIONADAS DE SEQ ID NOS:1-2; B) HVR-L1 DE SECUENCIAS SELECCIONADAS DE SEQ ID NOS: 6-9; C) HVR-L2 DE SECUENCIAS SELECCIONADAS DE SEQ ID NOS: 11-13; D) HRV-L3 DE SECUENCIAS SELECCIONADAS DE SEQ ID NOS: 15-18. DICHO ANTICUERPO SE FIJA AL DOMINO LNR-A Y EL DOMINIO HD-C DE Notch2, SIENDO UTIL EN EL TRATAMIENTO DE MELANOMAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10191708P | 2008-10-01 | 2008-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120080A1 true PE20120080A1 (es) | 2012-02-17 |
Family
ID=41349057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000807A PE20120080A1 (es) | 2008-10-01 | 2009-09-30 | Anticuerpos anti-notch2 y metodos de uso |
Country Status (18)
Country | Link |
---|---|
US (5) | US8404239B2 (es) |
EP (1) | EP2334331B1 (es) |
JP (2) | JP5710487B2 (es) |
KR (1) | KR101712214B1 (es) |
CN (1) | CN102170909B (es) |
AR (1) | AR073717A1 (es) |
AU (1) | AU2009298569A1 (es) |
BR (1) | BRPI0913827A2 (es) |
CA (1) | CA2736429A1 (es) |
CL (1) | CL2011000711A1 (es) |
ES (1) | ES2541726T3 (es) |
IL (1) | IL211623A0 (es) |
MX (1) | MX2011002928A (es) |
PE (1) | PE20120080A1 (es) |
RU (1) | RU2580029C2 (es) |
TW (1) | TW201018484A (es) |
WO (1) | WO2010039832A1 (es) |
ZA (1) | ZA201101651B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
MY155603A (en) | 2008-07-08 | 2015-11-13 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
AR073717A1 (es) * | 2008-10-01 | 2010-11-24 | Genentech Inc | Anticuerpos anti-notch2 de murino y humano, y metodos de uso |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
EP3050899B1 (en) * | 2010-09-27 | 2019-09-04 | Janssen Biotech, Inc. | Antibodies binding human collagen ii |
US9663573B2 (en) | 2011-10-05 | 2017-05-30 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
JP2015517529A (ja) * | 2012-05-16 | 2015-06-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Notch2/3抗体によって癌を治療するための方法 |
WO2014028446A1 (en) | 2012-08-13 | 2014-02-20 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
JP6527132B2 (ja) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | 肝臓がんの診断及び治療のための組成物及び方法 |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
CN108472201A (zh) * | 2015-09-26 | 2018-08-31 | 财团法人卫生研究院 | 用于治疗掉发之方法及组成物 |
GB201521447D0 (en) * | 2015-12-04 | 2016-01-20 | Ucb Biopharma Sprl | De novo antibody design |
WO2018222880A1 (en) * | 2017-05-31 | 2018-12-06 | Trustees Of Boston University | Mechano-activated control of gene expression |
AU2021308653A1 (en) * | 2020-07-17 | 2023-02-16 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
IE20030749A1 (en) | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US20050158859A1 (en) | 1995-09-29 | 2005-07-21 | Yale University | Manipulation of non-terminally differentiated cells using the Notch pathway |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
US6436650B1 (en) | 1997-07-23 | 2002-08-20 | Yale University | Activated forms of notch and methods based thereon |
US6692919B1 (en) | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
WO2000020576A2 (en) | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
US8084258B2 (en) | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
AU2001292750B2 (en) | 2000-09-22 | 2005-07-14 | Genentech, Inc. | Notch receptor agonists and uses |
EP1356048A2 (en) | 2000-12-04 | 2003-10-29 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7755007B2 (en) | 2003-04-17 | 2010-07-13 | K&H Manufacturing, Inc | Heated pet mat |
WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
WO2006068822A1 (en) | 2004-12-20 | 2006-06-29 | Genentech, Inc. | Notch receptor agonists and uses |
CA2630839C (en) | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
US20080241150A1 (en) * | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
BRPI0715989A8 (pt) | 2006-10-19 | 2018-03-13 | Genentech Inc | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
MY155603A (en) | 2008-07-08 | 2015-11-13 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
AR073717A1 (es) * | 2008-10-01 | 2010-11-24 | Genentech Inc | Anticuerpos anti-notch2 de murino y humano, y metodos de uso |
CA2765989C (en) * | 2009-06-18 | 2016-11-29 | Pfizer Inc. | Anti notch-1 antibodies |
-
2009
- 2009-09-30 AR ARP090103776 patent/AR073717A1/es unknown
- 2009-09-30 MX MX2011002928A patent/MX2011002928A/es active IP Right Grant
- 2009-09-30 PE PE2011000807A patent/PE20120080A1/es not_active Application Discontinuation
- 2009-09-30 BR BRPI0913827-7A patent/BRPI0913827A2/pt not_active IP Right Cessation
- 2009-09-30 KR KR1020117007489A patent/KR101712214B1/ko active IP Right Grant
- 2009-09-30 RU RU2011117237/10A patent/RU2580029C2/ru not_active IP Right Cessation
- 2009-09-30 JP JP2011530173A patent/JP5710487B2/ja active Active
- 2009-09-30 CA CA 2736429 patent/CA2736429A1/en not_active Abandoned
- 2009-09-30 US US12/570,267 patent/US8404239B2/en active Active
- 2009-09-30 AU AU2009298569A patent/AU2009298569A1/en not_active Abandoned
- 2009-09-30 ES ES09793181.0T patent/ES2541726T3/es active Active
- 2009-09-30 WO PCT/US2009/059028 patent/WO2010039832A1/en active Application Filing
- 2009-09-30 TW TW98133312A patent/TW201018484A/zh unknown
- 2009-09-30 EP EP20090793181 patent/EP2334331B1/en active Active
- 2009-09-30 CN CN200980139202.1A patent/CN102170909B/zh active Active
-
2011
- 2011-03-03 ZA ZA2011/01651A patent/ZA201101651B/en unknown
- 2011-03-08 IL IL211623A patent/IL211623A0/en unknown
- 2011-03-31 CL CL2011000711A patent/CL2011000711A1/es unknown
-
2013
- 2013-02-22 US US13/773,843 patent/US20140037643A1/en not_active Abandoned
- 2013-10-11 US US14/051,699 patent/US20140314782A1/en not_active Abandoned
-
2014
- 2014-06-06 US US14/298,488 patent/US20170204175A9/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015042089A patent/JP2015145379A/ja active Pending
-
2017
- 2017-07-21 US US15/656,967 patent/US20180057589A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2011117237A (ru) | 2012-11-10 |
TW201018484A (en) | 2010-05-16 |
AU2009298569A1 (en) | 2010-04-08 |
EP2334331B1 (en) | 2015-04-29 |
JP2015145379A (ja) | 2015-08-13 |
CL2011000711A1 (es) | 2012-07-20 |
ZA201101651B (en) | 2012-06-27 |
IL211623A0 (en) | 2011-05-31 |
CN102170909B (zh) | 2015-11-25 |
RU2580029C2 (ru) | 2016-04-10 |
CN102170909A (zh) | 2011-08-31 |
JP2012504634A (ja) | 2012-02-23 |
JP5710487B2 (ja) | 2015-04-30 |
CA2736429A1 (en) | 2010-04-08 |
KR101712214B1 (ko) | 2017-03-03 |
US20170204175A9 (en) | 2017-07-20 |
US20100080808A1 (en) | 2010-04-01 |
KR20110061600A (ko) | 2011-06-09 |
US20150104461A1 (en) | 2015-04-16 |
US8404239B2 (en) | 2013-03-26 |
US20140037643A1 (en) | 2014-02-06 |
EP2334331A1 (en) | 2011-06-22 |
MX2011002928A (es) | 2011-04-11 |
US20140314782A1 (en) | 2014-10-23 |
AR073717A1 (es) | 2010-11-24 |
BRPI0913827A2 (pt) | 2020-12-29 |
ES2541726T3 (es) | 2015-07-23 |
US20180057589A1 (en) | 2018-03-01 |
WO2010039832A1 (en) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120080A1 (es) | Anticuerpos anti-notch2 y metodos de uso | |
PE20141722A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
RS52452B (en) | Antibodies and Immunoconjugates and Their Use | |
ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
ES2628108T3 (es) | Anticuerpos multiespecíficos | |
NZ712765A (en) | Antibodies that bind csf1r | |
ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
RS52305B (en) | ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE | |
PE20120878A1 (es) | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS | |
PE20150211A1 (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
RS53924B1 (en) | NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE | |
PE20141693A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek | |
PE20120877A1 (es) | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS | |
BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
RS53157B (en) | SCLEROSTINE ANTIBODIES | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
RS52345B (en) | ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
AR096364A1 (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
CO6220835A2 (es) | Anticuerpos anti-robo4 y sus usos | |
NZ590890A (en) | Neutralizing anti-influenza a virus antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |